Source:http://linkedlifedata.com/resource/pubmed/id/14629267
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2003-11-21
|
| pubmed:abstractText |
Angiogenesis is a key process in tumour growth and metastasis, and Factor-VIII microvascular density has been found to influence prognosis among endometrial carcinoma patients. The CD105/endoglin antibody has been reported to preferentially bind to activated endothelial cells in tissues participating in angiogenesis, and we therefore wanted to compare the prognostic significance of CD105/endoglin to that of Factor-VIII. In a population-based endometrial carcinoma study with long (median 11.5 years) and complete patient follow-up, mean intratumour microvascular density (MVD) assessed using CD105/endoglin was investigated and compared with previous data for MVD assessed using Factor-VIII. MVD by CD105/endoglin was significantly correlated with MVD by Factor-VIII (p=0.001). However, tumours within the two groups defined by the upper and lower quartiles for CD105/endoglin-MVD were both significantly more often metastatic (FIGO-stage III/IV; p=0.03), with high tumour cell proliferation by Ki67 (p=0.007) and with reduced survival (p=0.036) as compared with the intermediate groups. In Cox regression analysis, CD105/endoglin-MVD showed independent prognostic influence when analysed together with patient age, FIGO stage, histologic subtype, histologic grade and Factor-VIII-MVD, while the latter lost its prognostic impact when CD105/endoglin was included. In the subgroup with high MVD, there was a tendency towards improved response to radiation therapy. In conclusion, CD105/endoglin-MVD is significantly associated with FIGO stage, tumour proliferation and prognosis in endometrial carcinoma, indicating that this is a better angiogenic marker in these tumours.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/ENG protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cell Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Cell Adhesion Molecule-1
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0903-4641
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
111
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1011-8
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:14629267-Antigens, CD,
pubmed-meshheading:14629267-Carcinoma, Endometrioid,
pubmed-meshheading:14629267-Endometrial Neoplasms,
pubmed-meshheading:14629267-Female,
pubmed-meshheading:14629267-Follow-Up Studies,
pubmed-meshheading:14629267-Humans,
pubmed-meshheading:14629267-Immunohistochemistry,
pubmed-meshheading:14629267-Microcirculation,
pubmed-meshheading:14629267-Neoplasm Staging,
pubmed-meshheading:14629267-Neovascularization, Pathologic,
pubmed-meshheading:14629267-Norway,
pubmed-meshheading:14629267-Prognosis,
pubmed-meshheading:14629267-Receptors, Cell Surface,
pubmed-meshheading:14629267-Regression Analysis,
pubmed-meshheading:14629267-Retrospective Studies,
pubmed-meshheading:14629267-Survival Rate,
pubmed-meshheading:14629267-Tumor Markers, Biological,
pubmed-meshheading:14629267-Vascular Cell Adhesion Molecule-1
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
|
| pubmed:affiliation |
Department of Pathology, The Gade Institute, Bergen, Norway. helga.salvesen@haukeland.no
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|